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he use of cell culture systems for the detection
of Calamydia tracaomatis is the gold standard.
However, the sensitivity of a single endocervical
specimen may be only 70-90.e- Unfortunately,
cell culture is labor intensive and requires 48 hours
for completion. These problems fostered the de-
velopment of simplified rapid diagnostic tests
which bypassed the issue of organism viability.
The first detection systems were based on
either immunodetection of solubilized chlamydia
antigens (enzyme immunoassay) or direct visualiza-
tion using chlamydia-specific fluorescin-conjugated
monoclonal antibodies (direct fluorescent antibody
test). The relative sensitivity and poorer positive
predictive values of these methods led ulti:mately
to their relative abandonment in favor of tests
based on DNA/rRNA hybridization.
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The ability of the DNA probe to detect both
Neisseria gonorroeae and C. tracomatis in a single
test has made nucleic acid probe testing an attrac-
tive alternative. The long-term cost of false-
negative gonococcal cultures outweighed the cost
differential between properly handled specific cul-
tures for N. gonorroeae and 6: tracomatis and a
DNA probe (Table 1).
Test of Cure
With the recent introduction of single-dose therapy
for both N. gonorroeae and C. tracomatis, routine
test of cure during the immediate post-therapy pe-
riod is not recommended by the Centers for Dis-
ease Control. The CDC recommends that test of
cure for N. gonorroeae or C. tracomatis be per-
formed 7-14 days after completion of therapy if
symptoms persist. While this strategy is probably
valid for men, its applicability to asymptomatic
women is not well documented. In the absence of
symptomology, why should one do a test of cure? If
a macrolide other than azithromycin has been uti-
lized, the probability of poor compliance is signifi-
cant. When compliance is questioned, a test of cure
is advocated. Seventy percent of treatment failures
with erythromycin appear to be related to compli-
ance problems. Published cure rates with macro-
lides, such as erythromycin, are not totally compa-
rable to those observed with doxycycline. A test of
cure may be warranted three weeks after comple-
tion of treatment with these antibiotics. With non-
cultured tests, residual chlamydial antigen and
nucleic acids, in the absence of viable organisms,
may result in a positive test. Such a positive result
can be misinterpreted as a treatment failure. False-
positive tests due to antigen persistence can occur
up to three weeks after doxycycline therapy.
A second situation which appears to warrant a
test of cure is that of an individual who is at high
risk for reinfection. High-risk women should be
rescreened one or two months after testing. By so
doing, both therapeutic failures and bases of rein-
fection can be identified. Should the culture for N.
gonorroeae be positive, one has the isolate for an-
tibiotic-sensitivity studies. In the case of C. tracao-
matis, the use of culture precludes antigens from
dead organisms causing a false-positive test.
Since the prevalence of infection in test of cure
is very low, tests with the highest positive predic-
tive value, e.g., culture when testing performed
less than three weeks after therapy, are advocated.
After three weeks, nucleic acid amplification tests
such as polymerase chain reaction (PCR) and ligase
chain reaction (LCR), which have high positive
predictive values, can be used.
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TABLE I. Cost of current screening test for
Neisseria gonorrhoeae (NG) and Chlamydia
trachomatis (CT)
Cost of culture for NG*
Cost of culture for CT*
Cost of DNA probe for NG/CT*
$18.50
$57.95
$88.00
Combined cost
$76.45
*Creighton University/Saint Joseph Hospital
TABLE 2. Cost comparison of test of cure when
either N. gonorrhoeae (NG) or C. trachomatis (CT)
is identified
Test Cost Differences
DNA probe NG/CT $88.00
Culture for CT $57.95 $30.05
Culture for NG $18.50 $61.50
*Creighton University/Saint Joseph Hospital
TABLE 3. Test systems selection for identification
of C. trachomatis
Clinical situation Test procedure of choice
Low-prevalence
screening
Sexual assault/abuse
Test of cure
Less than 3 weeks
after therapy
Greater than 3 weeks
after surgery
DNA hybridization (ultimately
amplified DNA probe technologies,
polymerase chain reaction, LCR)
Culture-only method recommended*
Culture
rRNA or DNA hybridization probes
*If culture is obtained within 48 hours after exposure, it is recom-
mended that a second culture be obtained in two weeks in the absence
of preventive therapy.
Use of Tests in the Context of Test of Cure
A recent survey of local practicing obstetric and
gynecologic clinicians has shown that the nucleic
acid probes are being used for test of cure. This is
an uneconomical use of technology (Table 2). The
cost of the DNA probe for both N. gonorrhoeae and
C. trachomatis at Creighton University/Saint Joseph
Hospital is $88.00. According to the CDC, the pub-
lic health price for amplification tests is below
$15.00, but this price is not available in the usual
practice situation. The use of DNA probe is predi-
cated on the superior sensitivity of this antigen-
based technique over culture recovery of environ-
mentally viable N. gonorrhoeae. Once the initial
screening test is positive for one isolate, cost-
efficacy dictates that the test of cure should be
culture for that organism unless the ability to do so
properly is lacking. A properly obtained culture for
N. gonorrhoeae entails culture media incubated prior
to plating, availability of ambient COz, and mini-
mal delay between sampling and incubation. The
test systems best suited for specific indications for
C. trachomatis are listed in Table 3. Use of DNA
probe as a test of cure is warranted only if both
organisms were initially identified or no other
means of documenting eradication is available.
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